Nine Anticipated FDA Approvals for January 2026 Guideline Central FDA Announces Change in Status of 12 Peptides SSRP Institute EllieMD Dihexa CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs